Skip to main content
Figure 3 | Molecular Cancer

Figure 3

From: Selective anticancer activity of a hexapeptide with sequence homology to a non-kinase domain of Cyclin Dependent Kinase 4

Figure 3

Clonogenic cell survival assays of RT112 human bladder cancer cells and H460 human non-small cell lung cancer cells exposed to PRGPRP vs PRRPGP as linear hexapeptides or in cyclic amphiphilic cassettes. A. Comparison of response of RT112 human bladder cancer cells to PRGPRP and THR53. B. Clonogenic cell survival of H460 human non-small cell lung cancer cells to THR53 (cyc-[FPPRGPRPVKLALKALAK]); THR54 (cyc-[PRGPRPVALKLALKLAL]) and THR79 (cyc-[PRGPRPvalklalkalal]). (Capitals signify L-amino acids, lower case signify D-amino-acids). C. Comparative clonogenic cell survival of RT112 human bladder cancer cells exposed to the linear end-capped hexapeptides PRGPRP or PRRPGP. D. Comparative clonogenic cell survival of H460 human non-small cell lung cancer cells exposed to the cyclic amphiphilic peptides: THR 53 (cyc-[FPPRGPRPVKLALKALAK]) or THR 53C (cyc-[FPPRRPGPVKLALKALAK]).

Back to article page

Molecular Cancer

ISSN: 1476-4598